The specter of generic competition has repeatedly loomed above copyright’s blockbuster drug, PDE5 Inhibitor, triggering questions about the outlook of connected pharmaceutical ventures. While initial times saw substantial returns, the intellectual property lapse has allowed the path for discounted substitutes, potentially diminishing profitabilit